Zydus Lifesciences gains USFDA approval for Jaythari tablets

Zydus Lifesciences Limited announced that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari® (Deflazacort) Tablets, available in 6 mg, 18 mg, 30 mg, and 36 mg dosages. Jaythari, a corticosteroid, is prescribed for treating Duchenne muscular dystrophy (DMD) in patients aged five years and older. Production will occur at Doppel Farmaceutici S.r.l.'s facility in Italy. As of March 31, 2025, the group holds 424 approvals and has filed 492 ANDAs since the fiscal year 2003-04. The stock code of Zydus Lifesciences Limited is BSE: 532321, NSE: ZYDUSLIFE.